FILTER
FILTERED INTERVIEW RESULTS
George Kwatia
PARTNER, PWC GHANA
PwC Ghana comments on how the mining industry and the Ghanian government are managing the impacts of the pandemic.
Osam Iyahen
SENIOR DIRECTOR NATURAL RESOURCES, AFRICA FINANCE CORPORATION
Africa Finance Corporation explains its role of investing in infrastructure across Africa in order to both assist and benefit from the growth that this will engender.
Will Coetzer & Jane Banks
MANAGING PARTNER & PRINCIPAL CONSULTANT, STRATUM INTERNATIONAL
Stratum International explains the shifts in the mining industry recruitment patterns.
John Kwofie & Ivan Doku
PRINCIPAL MINING ENGINEER AND COUNTRY MANAGER & PRINCIPAL RESOURCE GEOLOGIST AND COUNTRY MANAGER-DESIGNATE, SRK CONSULTING
An overview of the firm’s activities in West Africa.
Marc Kleiner & Kyle Kleiner
MANAGING DIRECTOR & SALES DIRECTOR, CONDRA
Condra manufactures and provides lifting equipment for mines across the world.
Stephen G. Roman
PRESIDENT & CEO, GLOBAL ATOMIC CORP.
Global Atomic Corp explains development at its Deva project in Niger.
Yannick Mbiya Ngandu
DIRECTOR, TRUST MERCHANT BANK (TMB) DRC
TMB is a rapidly expanding bank in DRC, and the only one to be based in the mining capital, Lubumbashi.
Noel Mabuma
CHIEF EXECUTIVE OFFICER, CONGO EQUIPMENT
Congo Equipment discusses supplying the mining industry in DRC.
John Dorward
PRESIDENT & CEO, ROXGOLD
Roxgold expands on the rapid development of its gold projects in West Africa.
Richard Young
PRESIDENT AND CEO, TERANGA GOLD CORPORATION
Teranga updates GBR on its gold projects in West Africa.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
